» Download Public Reports
40 reports
- Company report
- January 2012
- 12 pages
... These presentations are hosted by leadingcompanies in the field of biosimilars andoffer an opportunity to learn about the latestdevelopment and technology advancementsin the industry. If you would like to host ...
March 2012
... Robustness high serum stability, yet biodegradable tailored half-life extension for fabs, biologics, peptides etc. Unique ip exclusive to xl-protein production inexpensive manufacturing in e. Coli & cell ...
November 2012
... Represented by its new brand boehringer ingelheim bioxcellence . As a leading biopharmaceutical contract manufactu with more than 35 years of experience The company has brought 19 biopharmaceutical ...
February 2012
... How to desmoteplase to h. Lundbeck a/s ( Lundbeck ) And lundbeck enters into paion S existing agreement with bayer pharma ag ( Bayer ). The purchase price amounts to eur 20.1 Million. As a result, further ...
January 2012
... Fundamental requirements, such as conformance to gmps and compendial quality standards (e.G. Nonproprietary naming/identity; strength, quality, purity) the new biosimilars 351(k) marketing pathway has some ...
March 2012
... Such as sonication, are still commonly employed for bacterial cell disruption. Although effective at liberating proteins, sonicated samples can have reduced yield of active protein due to denaturation ...
September 2012
... Of antibody fragments in manufacturing increasing production of antibody fragments in e. Coli by various strategies, such as vector design, strain engineering, co-expressing host cell proteins and process ...
June 2012
... Fundamental requirements, such as conformance to gmps and compendial quality standards (e.G. Nonproprietary naming/identity; strength, quality, purity) the new biosimilars 351(k) marketing pathway has some ...
February 2013
... But this system lacks mechanisms to carry out posttranslational modifications. Today, plants represent an alternative for production of recombinant proteins. As bioreactors, they offer the possibility ...
March 2012
... Processes. Hence, they cannot be subject to the price regulation mechanisms for generics. The european medicines agency (ema) has explicitly stated that biosimilars are not generics by definition ...